Overview

Dysport Dose-Ranging Treatment of Platysmal Bands

Status:
Recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This is a double-blinded, dose-ranging study in the US to assess the efficacy, safety, and duration of response of abobotulinumtoxinA for the treatment of moderate to severe platysmal bands.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Clinical Testing of Beverly Hills

Collaborator:

Galderma R&D

Treatments:

abobotulinumtoxinA
Botulinum Toxins, Type A